Related Experiment Video
Updated: Jun 16, 2026
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
IGF-I, insulin and prostate cancer
Giovanna A Balarini Lima1, Lívia L Corrêa, Rafael Gabrich
1Serviço de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil. gibalarini@gmail.com
Arquivos Brasileiros De Endocrinologia E Metabologia
|February 4, 2010
Summary
This review explores the link between insulin-like growth factors (IGFs) and insulin with prostate cancer risk. It examines the evidence and potential therapies targeting these growth factors for future prostate cancer treatment.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Prostate cancer is a leading malignancy in adult men.
- Androgens are primary growth factors, but non-androgenic factors like IGF-I also play a role.
- The association between IGF-I and prostate cancer risk is known, but its diagnostic utility is limited compared to PSA.
Purpose of the Study:
- To review the physiopathological basis, epidemiological evidence, and animal models linking the IGF family and insulin to prostate cancer.
- To discuss potential future therapies targeting these growth factors for prostate cancer treatment.
Main Methods:
- Literature review of physiopathological, epidemiological, and animal model studies.
- Analysis of the role of IGF-I, IGFBP-3, and insulin in prostate cancer development and progression.
Main Results:
- The association between IGF-I and prostate cancer risk is well-established, though not enhancing PSA specificity.
- Evidence linking IGFBP-3 to prostate cancer risk is inconclusive.
- High insulin levels may be associated with aggressive prostate tumors.
Conclusions:
- The IGF family and insulin are implicated in prostate cancer.
- Further research into these growth factors may lead to novel therapeutic strategies for prostate cancer.
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...